State Street’s La Jolla Pharmaceutical Company LJPC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | – | Sell |
-98,941
| Closed | -$316K | – | 5033 |
|
|
2022
Q2 | $316K | Hold |
98,941
| – | – | ﹤0.01% | 4010 |
|
|
2022
Q1 | $422K | Buy |
98,941
+3,962
| +4% | +$17.3K | ﹤0.01% | 4118 |
|
|
2021
Q4 | $442K | Buy |
94,979
+1,500
| +2% | +$6.25K | ﹤0.01% | 4064 |
|
|
2021
Q3 | $373K | Hold |
93,479
| – | – | ﹤0.01% | 4097 |
|
|
2021
Q2 | $400K | Sell |
93,479
-302,041
| -76% | -$1.29M | ﹤0.01% | 3942 |
|
|
2021
Q1 | $1.68M | Sell |
395,520
-46,131
| -10% | -$254K | ﹤0.01% | 3503 |
|
|
2020
Q4 | $1.71M | Buy |
441,651
+33,620
| +8% | +$144K | ﹤0.01% | 3417 |
|
|
2020
Q3 | $1.64M | Buy |
408,031
+2,425
| +0.6% | +$10K | ﹤0.01% | 3276 |
|
|
2020
Q2 | $1.73M | Sell |
405,606
-3,842
| -0.9% | -$23.4K | ﹤0.01% | 3237 |
|
|
2020
Q1 | $1.72M | Sell |
409,448
-19,610
| -5% | -$124K | ﹤0.01% | 3119 |
|
|
2019
Q4 | $1.69M | Buy |
429,058
+1,505
| +0.4% | +$8.89K | ﹤0.01% | 3300 |
|
|
2019
Q3 | $3.76M | Buy |
427,553
+11,890
| +3% | +$112K | ﹤0.01% | 2933 |
|
|
2019
Q2 | $3.85M | Sell |
415,663
-9,354
| -2% | -$70.5K | ﹤0.01% | 2965 |
|
|
2019
Q1 | $2.73M | Buy |
425,017
+17,620
| +4% | +$115K | ﹤0.01% | 3037 |
|
|
2018
Q4 | $3.84M | Sell |
407,397
-1,239,720
| -75% | -$18.7M | ﹤0.01% | 2843 |
|
|
2018
Q3 | $33.2M | Buy |
1,647,117
+126,229
| +8% | +$3.3M | ﹤0.01% | 1824 |
|
|
2018
Q2 | $44.4M | Buy |
1,520,888
+40,600
| +3% | +$1.25M | ﹤0.01% | 1567 |
|
|
2018
Q1 | $44.1M | Buy |
1,480,288
+624,102
| +73% | +$20.1M | ﹤0.01% | 1500 |
|
|
2017
Q4 | $27.6M | Buy |
856,186
+109,694
| +15% | +$3.58M | ﹤0.01% | 1835 |
|
|
2017
Q3 | $26M | Sell |
746,492
-433,876
| -37% | -$14M | ﹤0.01% | 1836 |
|
|
2017
Q2 | $35.1M | Buy |
1,180,368
+828,081
| +235% | +$23.7M | ﹤0.01% | 1587 |
|
|
2017
Q1 | $10.5M | Buy |
352,287
+124,726
| +55% | +$3.18M | ﹤0.01% | 2348 |
|
|
2016
Q4 | $3.99M | Buy |
227,561
+13,495
| +6% | +$259K | ﹤0.01% | 2812 |
|
|
2016
Q3 | $5.09M | Buy |
214,066
+2,280
| +1% | +$43K | ﹤0.01% | 2556 |
|
|
2016
Q2 | $3.39M | Sell |
211,786
-3,627
| -2% | -$65.1K | ﹤0.01% | 2835 |
|
|
2016
Q1 | $4.5M | Sell |
215,413
-242,961
| -53% | -$4.33M | ﹤0.01% | 2607 |
|
|
2015
Q4 | $12.4M | Buy |
458,374
+289,222
| +171% | +$7.89M | ﹤0.01% | 2065 |
|
|
2015
Q3 | $4.7M | Buy |
169,152
+74,421
| +79% | +$2.35M | ﹤0.01% | 2552 |
|
|
2015
Q2 | $2.32M | Buy |
+94,731
| New | +$1.95M | ﹤0.01% | 3004 |
|
State Street's LJPC Position: Q3 2022 in Review
State Street sold out of La Jolla Pharmaceutical Company (LJPC) in Q3 2022, closing a stake of 98,941 shares — an estimated $316K sold.
State Street first reported a position in LJPC in Q2 2015 and held it in 29 quarters. The position peaked at $44.4M in Q2 2018. 0 funds tracked by Wall St. Rank hold LJPC as of Q3 2022.
- State Street reported no remaining La Jolla Pharmaceutical Company position as of Q3 2022 after selling out during the quarter.
- State Street sold 98,941 La Jolla Pharmaceutical Company shares in Q3 2022, an estimated $316K.
- State Street first reported a position in La Jolla Pharmaceutical Company in Q2 2015 and held it in 29 quarters.
- State Street's La Jolla Pharmaceutical Company position peaked at $44.4M in Q2 2018.
- 0 funds tracked by Wall St. Rank held La Jolla Pharmaceutical Company as of Q3 2022.
Based on State Street's 13F filing for Q3 2022, filed 15 Nov 2022.